INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 14, 2026 - 01:02

INOVIO has released its financial results for the first quarter of 2026, alongside a summary of recent business developments. The company's primary focus remains on the regulatory path for its lead candidate, INO-3107.

The Biologics License Application for INO-3107 is currently under active review by the U.S. Food and Drug Administration. This review is being conducted under the accelerated approval program, which is designed to speed up access to therapies for serious conditions that address an unmet medical need. INO-3107 is being developed for the treatment of recurrent respiratory papillomatosis, a rare and debilitating disease caused by the human papillomavirus.

Financially, INOVIO reported a net loss for the quarter, reflecting ongoing investment in research and development as well as manufacturing capabilities. The company stated that its cash position is sufficient to fund operations through key milestones, including the potential approval of INO-3107. Management emphasized that the next few months are critical as they work closely with the FDA to address any remaining questions from the review process.

Beyond the regulatory update, INOVIO continues to advance its pipeline of DNA-based immunotherapies. The company is also exploring partnerships to expand the application of its technology platform into other infectious diseases and cancers. No additional details on specific trial data or financial projections were provided in the release.